PTG-630 / Praetego - LARVOL DELTA

Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer's Disease (PRNewswire) - "Praetego Inc...is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA). The Phase 2 award advances Praetego's lead candidate, PTG-630, against Alzheimer's disease (AD)."

Financing • Alzheimer's Disease • CNS Disorders